KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Payables: 2018-2024

Historic Payables for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $106.2 million.

  • Esperion Therapeutics' Payables rose 279.69% to $132.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.7 million, marking a year-over-year increase of 246.73%. This contributed to the annual value of $106.2 million for FY2024, which is 234.90% up from last year.
  • As of FY2024, Esperion Therapeutics' Payables stood at $106.2 million, which was up 234.90% from $31.7 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Payables registered a high of $106.2 million during FY2024, and its lowest value of $17.6 million during FY2021.
  • Its 3-year average for Payables is $53.7 million, with a median of $31.7 million in 2023.
  • As far as peak fluctuations go, Esperion Therapeutics' Payables plummeted by 66.22% in 2021, and later surged by 234.90% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Payables (Yearly) stood at $52.0 million in 2020, then plummeted by 66.22% to $17.6 million in 2021, then skyrocketed by 31.21% to $23.0 million in 2022, then spiked by 37.66% to $31.7 million in 2023, then soared by 234.90% to $106.2 million in 2024.